Compositions and Methods for the Delivery of Therapeutics

Abstract

The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.

1 . A nanoparticle comprising at least one CCR5 receptor antagonist, at least one hydrophobic polymer, and at least one surfactant. 
     
     
         2  The nanoparticle of  claim 1 , wherein said hydrophobic polymer is poly(lactic-co-glycolic acid). 
     
     
         3 . The nanoparticle of  claim 1 , wherein said surfactant is a glycerophospholipid. 
     
     
         4 . The nanoparticle of  claim 3 , wherein said glycerophospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG). 
     
     
         5 . The nanoparticle of  claim 4 , wherein said glycerophospholipid is conjugated to polyethylene glycol. 
     
     
         6 . The nanoparticle of  claim 1 , wherein said CCR5 receptor antagonist is maraviroc. 
     
     
         7 . The nanoparticle of  claim 1 , wherein said nanoparticle comprises a surfactant linked to at least one targeting ligand. 
     
     
         8 . The nanoparticle of  claim 7 , wherein, said targeting ligand is a macrophage targeting ligand. 
     
     
         9 . The nanoparticle of  claim 8 , wherein said macrophage targeting ligand is folate. 
     
     
         10 . The nanoparticle of  claim 1 , wherein said CCR5 receptor antagonist is maraviroc, wherein said hydrophobic polymer is poly(lactic-co-glycolic acid), wherein said surfactant is a glycerophospholipid, optionally conjugated to polyethylene glycol. 
     
     
         11 . The nanoparticle of  claim 10 , wherein said glycerophospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG). 
     
     
         12 . A pharmaceutical composition comprising at least one nanoparticle of  claim 1  and at least one pharmaceutically acceptable carrier. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein said pharmaceutical composition further comprises at least one other anti-HIV compound. 
     
     
         14 . A method for treating, inhibiting, and/or preventing an HIV infection in a subject in need thereof, said method comprising administering to said subject a nanoparticle of  claim 1 . 
     
     
         15 . The method of  claim 14 , further comprising the administration of at least one additional anti-HIV compound.